Business Wire

MA-VERISTAT

Share
Veristat Appoints Colleen Pelton Chief Talent Officer

Veristat , a scientific-minded global clinical research organization (CRO), announced the appointment of Colleen Pelton to the role of Chief Talent Officer. Ms. Pelton joins Veristat following an impressive record of success in executive HR roles, most recently at Dental Services Group, St. Jude Medical, and Smith & Nephew during which time her responsibilities included the integration of acquired businesses and accelerating growth globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005293/en/

“Veristat is rapidly solidifying its position as a trusted leader in the design and implementation of global clinical trials of life-enhancing therapies,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “This is a time of tremendous opportunity for our company as we scale our talent and capabilities to produce positive value for an increasing number of sponsors. I am delighted to welcome Colleen to the leadership team. Colleen’s contributions will support the growing complexities of our worldwide business by bringing measurable value and ensuring we advance our reputation of having the highest-quality, scientific-minded workforce in the industry.”

In her role, Colleen will tap her 30 years of experience to lead the company’s global Talent and Culture function including global HR management, strategic talent planning, recruitment and training, career growth and development, organizational design, diversity, and leadership development.

“I have been presented with an exciting opportunity as Veristat executes on its clearly defined strategy,” said Colleen. “I am pleased to play a role in supporting the company’s growth through talent development and fostering our culture of collaboration. Throughout my career, my inspiration has been derived from the lives touched by the solutions put forward by the organizations I have served. With Veristat, this inspiration is magnified given the company’s focus on rare and challenging diseases. I look forward to being part of this important journey and supporting the career growth of such a talented global team with a broad set of development opportunities.”

Colleen is a Florida, U.S. native, and graduated from the University of Florida where she received a B.A. in Communications. Her wide-ranging expertise spans the design and implementation of global talent management and acquisition-related initiatives for billion-dollar global enterprises operating in 30+ markets with thousands of employees. Colleen has served as a respected member of senior management teams driving various aspects of the business, consulting with senior executives on evolving business strategies, fostering a positive workplace culture, leadership development, and adapting to ever-changing work environments.

About Veristat

Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 19:11:00 CET | Press release

Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an ex

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release

− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o

Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release

CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr

Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release

Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid

Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 14:12:00 CET | Press release

Digital payments veteran Rachelle Alexis Lim now spearheads MultiSafepay’s operational strategy as it brings its innovative omnichannel payment platform to businesses of all sizes across Europe, driving inclusive growth for SMEs. Founder, Olaf Geurs, who has led MultiSafepay for nearly three decades will remain Chief Technology Officer and hold his position on the board of directors. In this role he will remain instrumental to driving innovation. Since the start of its strategic partnership with global payment and digitisation provider Antom, MultiSafepay's transaction volume has nearly doubled, and its merchant base has increased by over a quarter. MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye